Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Type 2 Diabetes or Pre-Diabetes, and Preserved Ejection Fraction Heart Failure (Preserved-HF Trial)
Drug study looking at effects of dapagliflozin on patients with Heart Failure and Preserved Ejection Fraction and diabetes or pre-diabetes.
Sponsor: Saint Luke's Hospital of Kansas City, Mid America
Enrolling: Male and Female Patients
IRB Number: AAAR2503
U.S. Govt. ID: NCT03030235
Contact: Andrea Kim: 212-305-1368 / ak451@cumc.columbia.edu
Additional Study Information: A drug study looking at the effects of 10 mg Dapagliflozin vs. Placebo in patients with Heart Failure and Preserved Ejection Fraction (HFpEF) with either diabetes or pre-diabetes.
This study is closed
Investigator
Mathew Maurer, MD
Do You Qualify?
Do you have Heart Failure with Preserved Ejection Fraction? Yes No
Do you have diabetes or pre-diabetes? Yes No
Are you over the age of 18 years old? Yes No
Are you on a diuretic or "water pill"? Yes No
Have you had an ECHO in the past 18 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Andrea Kim
ak451@cumc.columbia.edu
212-305-1368
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE